Isotalo T, Talja M, Tammela T L, Törmälä P, Paasimaa S, Andersson L
Division of Urology, Tampere University Hospital, Finland.
Urol Res. 1999 Apr;27(2):149-52. doi: 10.1007/s002400050101.
Forty to 75% of strictures recur within 2 years of urethrotomy and the essential problem remains how to prevent the edges of the cut stricture from adhering to each other and the scar from shrinking. To solve this problem different kinds of urethral stents have been used. Recently a new bioabsorbable self-expanding urethral stent was developed by our group. The core consists of self-reinforced (SR) poly-L-lactic acid (PLLA) and the coating is made of an amorphous copolymer of caprolactone and D,L-lactic acid [P(epsilon-CL/ D,L-LA)]. The aim of our present study was to test the cytotoxicity of the new material used to coat the SR-PLLA urethral stent utilizing the thymidine incorporation method (DNA synthesis inhibition test). The new materials showed no acute toxicity and can be regarded as biocompatible in medical devices.
尿道切开术后40%至75%的狭窄会在2年内复发，关键问题仍然是如何防止切开的狭窄边缘相互粘连以及瘢痕收缩。为了解决这个问题，人们使用了各种尿道支架。最近，我们团队研发了一种新型生物可吸收自膨胀尿道支架。其核心由自增强（SR）聚-L-乳酸（PLLA）组成，涂层由己内酯与D，L-乳酸的无定形共聚物[P(ε-CL/D，L-LA)]制成。我们目前这项研究的目的是利用胸腺嘧啶核苷掺入法（DNA合成抑制试验）来测试用于包覆SR-PLLA尿道支架的新材料的细胞毒性。这些新材料没有显示出急性毒性，在医疗设备中可被视为具有生物相容性。
